OKYO Pharma Ltd announced its participation in the virtual BTIG Biotechnology Conference 2026 scheduled for July 28-29, 2026. Management representatives attending include CEO Robert J. Dempsey, CFO Keeren Shah, and CMO Flavio Mantelli. The company plans to initiate a global Phase 3 pivotal clinical trial in the second half of 2026, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for neuropathic corneal pain (NCP). OKYO Pharma is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain and anterior segment eye diseases.
